Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NRSN
NRSN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NRSN News
NeuroSense to Present PrimeC Data at AD/PD 2026 Conference
6d ago
PRnewswire
NeuroSense Publishes ALS Clinical Trial Results in JAMA Neurology
Mar 16 2026
PRnewswire
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 10 2026
Benzinga
NeuroSense Reports New ALS Treatment Data
Mar 09 2026
PRnewswire
NeuroSense Releases New ALS Treatment Data
Feb 18 2026
PRnewswire
NeuroSense Secures Australian Patent, Strengthening Global IP for PrimeC
Feb 09 2026
PRnewswire
NeuroSense Therapeutics Secures U.S. Patent for PrimeC Alzheimer’s Therapy Valid Through 2043
Jan 21 2026
seekingalpha
NeuroSense Secures U.S. Patent for PrimeC Combination in Alzheimer's Treatment
Jan 21 2026
PRnewswire
NeuroSense Appoints Alzheimer's Expert Prof. Arnold to Advance PrimeC Development
Jan 08 2026
PRnewswire
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
NeuroSense Completes Safety Analysis of PrimeC for Alzheimer's with Favorable Data
Dec 23 2025
NASDAQ.COM
NeuroSense Completes Safety Analysis of PrimeC in Alzheimer's Phase 2 Study
Dec 22 2025
PRnewswire
NeuroSense Resumes Regulatory Progress for PrimeC in Canada, Anticipates NDS Submission by Mid-2026
Dec 04 2025
PRnewswire
D. Boral Capital Reiterates Buy Rating for NeuroSense Therapeutics with $14 Price Target Intact
Nov 24 2025
Benzinga
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Nov 24 2025
PRnewswire
NeuroSense to Host Investor Webinar on December 8, 2025
Nov 03 2025
PRnewswire
Show More News
